Frazier Healthcare VI

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus. The Carlsbad, California-based company was established by Uri Lopatin in 2020.

SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore (the “Territory”). SanReno Therapeutics formed with JV of Chinook Therapeutics and Frazier Healthcare Partners and Pivotal bioVenture Partners China.

Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.

Silence Therapeutics is a biotechnology company based in the United Kingdom that specializes in the discovery and development of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company utilizes short interfering RNA (siRNA) technology to target and degrade specific messenger RNAs, thereby modulating gene expression. Its notable product candidates include SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to lower lipoprotein levels and reduce cardiovascular risks. Silence Therapeutics also engages in strategic collaborations, including a partnership with AstraZeneca to advance small interfering RNA therapeutics for multiple disease areas. Established as SR Pharma plc, the company rebranded to Silence Therapeutics in 2007 and is headquartered in London.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Radionetics Oncology is a biopharmaceutical company dedicated to the discovery and development of innovative radiotherapeutics aimed at treating various oncology indications. The company specializes in creating non-peptide and small molecule agents that facilitate the targeted delivery of therapeutic radioisotopes to solid tumors. This focus positions Radionetics Oncology to address the growing need for advanced treatment options in oncology, enhancing the capabilities of medical professionals in managing cancer.

Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Hummingbird Bioscience Pte. Ltd. is a biotechnology company based in Singapore, specializing in the development of antibody-based therapeutics for cancer. Founded in 2014, it leverages advances in systems biology and a proprietary rational antibody discovery platform to create innovative biotherapeutics. The company focuses on a diverse pipeline of drug candidates, which includes lead assets such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both aimed at addressing significant unmet medical needs in oncology. Hummingbird Bioscience has established strategic collaborations with notable organizations such as Cancer Research UK and Amgen, and it has received a product development grant from the Cancer Prevention and Research Institute of Texas. The company's goal is to enhance treatment options for patients facing challenging cancer diagnoses through its cutting-edge research and development efforts.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.

Seraxis is a private biotechnology company founded in March 2013, with operations in Singapore and the United States, and a GMP lab located in Germantown, Maryland. The company specializes in developing innovative cell replacement therapies aimed at treating insulin-dependent diabetes. Their primary focus is on creating a solution that allows for the production of insulin to manage glucose levels, providing patients with a long-term cure that does not necessitate immuno-suppression. Seraxis is dedicated to advancing its novel cell and encapsulation technologies to bring this treatment to clinical use as efficiently as possible.

CSafe specializes in the design and manufacture of cold chain solutions and mobile refrigeration units tailored for various sectors, including medical devices, pharmaceuticals, public health, military, and disaster relief. The company provides both passive and active containers for transporting temperature-sensitive materials, making it a key player in the logistics of sensitive goods. Additionally, CSafe offers a range of services such as leasing, active qualification and validation, training, and packaging qualification. With a global presence, the company serves its customers through a network of partners, service centers, and distributors, ensuring comprehensive support for cold chain logistics. Founded in 1989 and headquartered in Dayton, Ohio, CSafe is recognized for its unique offerings in active air cargo solutions and specialized services for cell and gene therapies.

Avadel Pharmaceuticals plc is a specialty pharmaceutical company based in Dublin, Ireland, with operations in the United States and France. The company focuses on developing innovative pharmaceutical products, particularly in the areas of urology, central nervous system disorders, and hospital settings. Avadel is advancing FT218, currently in Phase 3 clinical trials, aimed at treating narcolepsy patients experiencing excessive daytime sleepiness and cataplexy. Additionally, the company markets three sterile injectable medications used in hospitals: Akovaz for managing hypotension during anesthesia, Bloxiverz for reversing neuromuscular blockade after surgery, and Vazculep for treating significant hypotension. Avadel was originally founded as Flamel Technologies SA and rebranded in January 2017. It was incorporated in 2015 and continues to prioritize the development of safe and effective treatment options for patients.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative dermatologic and immunologic therapies. Founded by the team behind Vicept Therapeutics, Aclaris is dedicated to addressing significant unmet medical needs in dermatology and immunology, particularly in areas lacking FDA-approved treatments. The company operates in two main segments: therapeutics and contract research. The therapeutics segment focuses on creating novel drug candidates for immuno-inflammatory diseases, while the contract research segment generates revenue by providing laboratory services. Aclaris's pipeline includes drug candidates such as Zunsemetinib, an oral MK2 inhibitor, aiming to fill critical treatment gaps in the healthcare landscape.

Inipharm Inc. is a biopharmaceutical company based in Bellevue, Washington, established in 2018. The company specializes in discovering and developing therapies for severe liver diseases, particularly nonalcoholic steatohepatitis (NASH). Inipharm focuses on small-molecule drugs that target HSD17B13, a gene linked to various liver conditions. By modulating this gene's activity, Inipharm aims to reduce liver damage, inflammation, and fibrosis, addressing significant unmet medical needs in the treatment of liver diseases.

Accuity Delivery Systems, LLC specializes in clinical documentation, coding, and client education services tailored for the healthcare sector. The company focuses on clinical documentation improvement, assisting healthcare providers in applying practice protocols to enhance care delivery. It also offers coding and quality assurance services to ensure appropriate reimbursement and compliance with documentation standards. Additionally, Accuity provides educational programs for hospital providers and coding staff, emphasizing the importance of accurate documentation. The company's business intelligence and technology services further support healthcare organizations by integrating IT solutions and analytics, enabling informed decision-making based on the extensive data generated daily. Founded in 2015, Accuity has its headquarters in New York, New York, with an additional office located in Las Vegas, Nevada.

Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Founded in 2018, the company aims to address unmet medical needs by discovering and commercializing innovative treatments for endocrine diseases that affect hormonal regulation in the body. MBX Biosciences focuses on creating first-in-class therapies, particularly utilizing peptides to target rare genetic conditions related to glandular hormone secretion.

Lassen Therapeutics focuses on developing antibody biotherapeutics aimed at treating fibrosis, rare diseases, and cancer. The company's lead candidate, LASN01, is a monoclonal antibody that specifically targets the IL-11 receptor alpha, which is a key mediator in fibrosis and tumor growth. By inhibiting IL-11, Lassen Therapeutics aims to offer a more effective treatment alternative compared to traditional approaches that target other factors like TGF-β and CTGF. The company leverages advanced antibody technologies to create innovative therapeutics that address the complexities of the tumor microenvironment and the role of cytokines in various diseases, ultimately striving to enhance patient outcomes for those affected by serious health conditions.

Lengo Therapeutics a biopharmaceutical company focused on the discovery and development of cancer treatments. Lengo works to identify several mutations in cancers that were not well addressed by existing therapeutics, helping medical practitioners and pharma companies to target driver mutations in oncology.

Dascena, Inc. is a technology company based in Oakland, California, specializing in the development of algorithm software for diagnostics and biomarkers. Founded in 2018, Dascena creates machine learning algorithms designed to enhance early disease intervention and improve patient care outcomes. Its primary product, AlgoDiagnostics, autonomously processes electronic health record data to identify conditions such as acute decompensation, sepsis, and acute kidney injury. By leveraging advanced algorithms, Dascena aims to facilitate timely medical responses and support healthcare professionals in delivering better patient care.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.

Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.

EPTAM Precision, based in Northfield, New Hampshire, specializes in the manufacture of precision-machined plastic and metal components, primarily serving industries such as medical, aerospace, and semiconductor. Founded in 1981, the company offers a wide range of products, including surgical instruments, medical implants, and components for energy and military applications. With a focus on high-quality and tight-tolerance machining, EPTAM provides contract production services that encompass polymer machining, metal components, laser cutting, welding, and plastic injection molding. The company supports its clients through value-added services like component design, engineering, program management, and process validation, ensuring that challenges during the design and manufacturing stages are effectively addressed. Following its acquisition of Relius Medical in 2018, EPTAM has positioned itself as a single-source provider for precision manufacturing solutions, helping to meet the demands of emerging commercial technologies.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, specializing in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions and other diseases with high unmet needs. The company's lead product candidate, TP-03, is currently undergoing Phase IIb/III trials for the treatment of blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. In addition to TP-03, Tarsus is advancing other candidates such as TP-04 for the treatment of rosacea and TP-05 aimed at Lyme disease prophylaxis and malaria reduction. With a focus on addressing significant market opportunities, Tarsus Pharmaceuticals is committed to providing first-in-class therapies where treatment options are currently limited.

Epizyme, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing epigenetic medicines for cancer and other diseases. The company has achieved a significant milestone with its approved product, Tazemetostat, which is used for treating metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed and refractory follicular lymphoma and high-risk diffuse large B-cell lymphoma. Epizyme is also engaged in developing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, alongside inhibitors targeting PRMT5 and PRMT1 for solid tumors and blood cancers. The company collaborates with several industry leaders and research organizations to advance its innovative therapeutic programs, reflecting its commitment to translating epigenetic research into effective treatments. Founded in 2007, Epizyme aims to reshape cancer treatment through its focus on molecularly targeted drugs.

Bellus Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, focused on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. Additionally, the company is advancing KIACTA™, a novel treatment for AA amyloidosis and sarcoidosis, both rare diseases affecting renal and pulmonary functions, respectively. KIACTA™ is in the data review stage following a Phase 3 study. Bellus Health is also developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies in progress. Furthermore, the company has a research-stage project aimed at treating AL amyloidosis, a condition characterized by the accumulation of amyloid proteins in various organs. Bellus Health is dedicated to addressing unmet medical needs through its innovative drug development pipeline.

IVERIC bio is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, particularly age-related and orphan retinal conditions. The company is advancing several candidates, including Fovista, which has completed Phase IIb clinical trials as a combination treatment with anti-VEGF drugs for wet age-related macular degeneration (wet AMD). Additionally, IVERIC bio is developing ARC1905, a selective inhibitor of complement factor C5, which has completed Phase I/IIa clinical trials aimed at treating wet AMD. Founded in 2007 and headquartered in New York, IVERIC bio is dedicated to addressing unmet medical needs in the field of eye care.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on developing gene therapy product candidates that utilize its proprietary NAV Technology Platform, which is based on adeno-associated virus (AAV) gene delivery. This platform aims to address genetic defects and enable cells to produce therapeutic proteins or antibodies to combat various diseases. The company's lead candidate, RGX-314, is currently undergoing Phase I/IIa clinical trials for wet age-related macular degeneration. Other notable product candidates include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia, all in various stages of clinical trials. Additionally, REGENXBIO licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has partnered with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

MedData, Inc. specializes in revenue cycle management and patient financial lifecycle services. Established in 1980 and headquartered in Brecksville, Ohio, with additional locations in Grand Rapids, Michigan; Roseville, California; Bellevue, Washington; and Peoria, Illinois, the company offers a comprehensive range of services. These include coding and billing, professional fee and facility billing, insurance follow-up and recovery, payment compliance, and Medicaid compliance. MedData also provides patient pay services such as consolidated statements, extended business office services, accounts receivable conversions, call center outsourcing, point-of-service payment processing, patient communications, and appointment scheduling. The company aims to enhance patient satisfaction while ensuring efficient financial management for healthcare providers. MedData was previously a subsidiary of MEDNAX, Inc.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.

Comprehensive Pharmacy Services, Inc. (CPS) provides a broad range of pharmacy support services to over 800 hospitals and healthcare facilities across the United States. Founded in 1971 and headquartered in Memphis, Tennessee, CPS specializes in inpatient hospital pharmacy services, clinical consulting, and operational assessments. The company addresses various challenges faced by healthcare providers, including high drug costs, specialty pharmacy management, and operational efficiency. CPS also offers consulting solutions that encompass compliance, medication safety, sterile compounding, and pharmacy analytics. Through its extensive service offerings, CPS aims to enhance the quality and effectiveness of pharmacy operations within healthcare settings.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Developer of antibiotic drugs intended to provide novel therapeutics for serious antibiotic-resistant infections. The company's drugs include the development of novel-class antibiotics to address the expanding problem of multi-drug resistant gram-negative bacteria, enabling patients to combat with potentially deadly pathogens.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

Sojournix, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative therapies for women's health and neuroendocrine disorders. Founded in 2016, the company is advancing SJX-653, a selective neurokinin-3 antagonist designed as a non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause. By aiming to provide safe and effective alternatives to current treatment options, Sojournix seeks to improve healthcare outcomes for women suffering from these conditions.

Atlanta Gastroenterology Associates is a leading gastroenterology practice located in Georgia, specializing in the detection and treatment of digestive and liver diseases, including colon cancer. The organization offers a wide range of services, including diagnosis and treatment of digestive disorders, gastroenterology surgery, anesthesia management, pathology services, and clinical research. By providing comprehensive digestive healthcare, Atlanta Gastroenterology Associates aims to deliver quality care to patients across Georgia and the southeastern United States at an affordable cost.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.

Krystal Biotech is a biopharmaceutical company based in Pittsburgh, Pennsylvania, focused on developing gene therapies for patients with rare skin diseases in the United States. Its primary candidate, beremagene geperpavec (B-VEC), is designed to treat dystrophic epidermolysis bullosa and has completed Phase I/II clinical trials. Additionally, the company is advancing KB105, which is in Phase I/II trials for autosomal recessive congenital ichthyosis, while KB301 and KB104 are in preclinical stages targeting aesthetic skin conditions and Netherton Syndrome, respectively. Krystal Biotech utilizes its proprietary STAR-D gene therapy platform to create innovative treatments that offer significant clinical benefits. Founded in 2015, the company aims to broaden its pipeline to address various dermatological conditions in the future.

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

Mavupharma Inc., founded in 2016 and based in the United States, focuses on the development of innovative therapies aimed at treating cancer and infectious diseases. The company is engaged in creating non-nucleotide, conditional modulators of the STING pathway, which plays a crucial role in the immune response. As of July 2019, Mavupharma operates as a subsidiary of AbbVie Inc., benefiting from the larger organization's resources and expertise in the pharmaceutical industry.

At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.

Alteon Health, LLC is a provider of outsourced healthcare practice management services based in The Woodlands, Texas. The company specializes in supporting emergency departments and hospital-based urgent care centers, offering a range of services including emergency medicine, hospitalist medicine, critical care, post-acute care, and virtual and home health services. Alteon Health aims to improve healthcare outcomes for hospitals, physicians, and patients by emphasizing patient-focused care and leveraging physician-led innovation and data-driven practices. Through effective healthcare partnerships, the company seeks to empower its physicians and staff to deliver high-quality care.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the global challenge of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to treat uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. The company's goal is to provide effective solutions for serious infections caused by resistant bacteria, thereby improving patient outcomes and addressing the limitations of existing antibiotic treatments.

Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.

Recognized as the number one orthopedic group since 2012 by Ranking Arizona, The CORE Institute, was founded to fulfill a vision of excellence in patient care encompassing the entire spectrum of musculoskeletal and neurosciences care. Consistent with our mission, The CORE Institute delivers the best in musculoskeletal and neurological care, built upon a foundation of pioneering research, academics, community service, and a passion for excellence in patient care. It is now one of the premier patient care destinations in the World and cares for patients from around the globe.

Matrx Medical Network specializes in providing in-home health risk assessment services for Medicare Advantage plans. The company conducts one-on-one evaluations carried out by licensed Nurse Practitioners who perform non-invasive physical exams, gather detailed medical histories, and assess the member's living conditions and medications. These assessments are designed to identify risk factors that may require further medical attention, and the Nurse Practitioners also offer health information and recommendations for additional evaluations. Established in 2001, Matrx has become one of the largest providers of prospective health assessments in the United States, completing over 224,000 assessments in 2012 alone. With its headquarters in Scottsdale, Arizona, and a member outreach center in Clearwater, Florida, Matrx operates across more than 30 states, delivering comprehensive care management services to enhance the health of its members. The company is owned by Welsh, Carson, Anderson & Stowe.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).

Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for the treatment of diseases affecting hospitalized patients. The company's primary product in development is ZOLYD, an investigational injectable antibiotic aimed at addressing serious and life-threatening infections caused by multi-drug resistant gram-negative and gram-positive bacteria. Founded in 2013, Zavante Therapeutics operates as a subsidiary of Nabriva Therapeutics plc, with a commitment to improving patient outcomes in critical care settings.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the global challenge of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem aims to treat uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. The company's goal is to provide effective solutions for serious infections caused by resistant bacteria, thereby improving patient outcomes and addressing the limitations of existing antibiotic treatments.

At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. It was founded in 2011 and headquartered in Newton, Massachusetts.

Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.

Calibrium is an emerging privately held biopharmaceutical company focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, Calibrium’s Chief Executive Officer, and Richard DiMarchi, PhD, Calibirum’s Chief Scientific Officer.

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapeutic antibodies for inflammation and immuno-oncology. The company’s key product candidates include Etokimab, an anti-IL-33 treatment for atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis; and several immune cell modulating antibodies, including checkpoint agonists for autoimmune diseases. AnaptysBio's pipeline features notable immuno-oncology candidates such as TSR-042 (anti-PD-1), TSR-022 (anti-TIM-3), and TSR-075 (anti-PD-1/LAG-3 bispecific). The company employs a proprietary platform based on somatic hypermutation for antibody discovery and optimization, addressing unmet medical needs in therapeutic applications. AnaptysBio has formed partnerships with various organizations, including TESARO and Celgene, to enhance its research and development efforts. Founded in 2005, AnaptysBio has established itself in the biotechnology sector as a developer of innovative therapies targeting significant health challenges.

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.

Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and marketing small molecule pharmaceuticals, particularly vanoxerine, which is a therapeutic candidate for treating atrial fibrillation and atrial flutter. Originally founded in 2006 as ChanRx Corp., the company rebranded to Laguna Pharmaceuticals in February 2015. Headquartered in La Jolla, California, Laguna Pharmaceuticals aims to address the medical needs associated with atrial fibrillation, a prevalent arrhythmia linked to serious cardiovascular events such as heart attacks and strokes.

Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.

Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. It was founded in 2011 and headquartered in Newton, Massachusetts.

Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.

Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer, particularly in the fields of hematology and oncology. Its lead candidate, momelotinib, is a selective JAK1, JAK2, and ACVR1 inhibitor that has been evaluated in two Phase 3 trials for myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, currently undergoing two Phase 1/2 clinical trials to explore its potential as a monotherapy and in combination with other therapies. Additionally, Sierra is developing SRA141, a small molecule inhibitor of cell division cycle 7 kinase, which is in preclinical research stages. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology retains global commercialization rights for its product candidates and aims to achieve successful registration and commercialization of its innovative therapies targeting the DNA Damage Response network.

PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.

PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.

Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development of innovative non-opioid medications aimed at treating lumbar radicular pain. The company focuses on creating products that address the needs of pain management practitioners and their patients, particularly those suffering from back pain. By prioritizing clinical and commercial development, Semnur aims to enhance the efficacy and safety of pain management therapies, ultimately improving treatment outcomes for underserved patient populations.

Alcresta Therapeutics, Inc. develops and commercializes enzyme-based products aimed at treating gastrointestinal disorders and rare diseases. The company's primary offering, RELiZORB, is a digestive enzyme cartridge designed to replicate the function of pancreatic lipase for adults on enteral tube feeding who struggle to break down and absorb fats. Established in 2011 and based in Warren, New Jersey, Alcresta focuses on innovative, point-of-care nutritional products that enhance nutrition and manage health conditions for various populations, including infants, aging adults, and individuals with acute or chronic diseases. The company leverages its expertise in both adult and pediatric nutrition, along with protein manufacturing and regulatory knowledge, to address the unmet nutritional needs of those with compromised health.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases. It offers late stage development, and early stage development. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a leading cause of blindness globally. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS), fundamentally changing the approach to glaucoma management. Their flagship product, the iStent®, launched in the United States in 2012, is recognized as one of the smallest medical devices ever approved by the FDA, designed to reduce intraocular pressure in patients with mild-to-moderate open-angle glaucoma. In addition to the iStent, Glaukos is expanding its product pipeline with the iStent SA, a trabecular micro-bypass system designed for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to address a wide range of glaucoma disease states with its comprehensive portfolio of injectable micro-scale therapies.

Scilex Holding Company, through its subsidiary Scilex Pharmaceuticals, Inc., is engaged in the development and commercialization of pharmaceutical products aimed at pain management. The company specializes in acquiring late-stage clinical products, including both generic and branded generic medications, with a particular focus on innovative delivery methods such as transdermal patches. These products are designed to address pain conditions, notably post-herpetic neuralgia. Scilex operates within the United States, Canada, Mexico, and Latin America, serving a diverse customer base through wholesalers, distributors, and retailers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Scilex is dedicated to providing effective solutions for patients suffering from various pain conditions.

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

Alcresta Therapeutics, Inc. develops and commercializes enzyme-based products aimed at treating gastrointestinal disorders and rare diseases. The company's primary offering, RELiZORB, is a digestive enzyme cartridge designed to replicate the function of pancreatic lipase for adults on enteral tube feeding who struggle to break down and absorb fats. Established in 2011 and based in Warren, New Jersey, Alcresta focuses on innovative, point-of-care nutritional products that enhance nutrition and manage health conditions for various populations, including infants, aging adults, and individuals with acute or chronic diseases. The company leverages its expertise in both adult and pediatric nutrition, along with protein manufacturing and regulatory knowledge, to address the unmet nutritional needs of those with compromised health.

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.

Kalidex Pharmaceuticals, Inc. manufactures pharmaceuticals. The company was incorporated in 2010 and is based in Menlo Park, California.

Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. It was founded in 2011 and headquartered in Newton, Massachusetts.

Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. The company’s internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.

Silvergate Pharmaceuticals, Inc. develops and commercializes pediatric medications. The company markets its products under the Epaned brand name. Silvergate Pharmaceuticals, Inc. was incorporated in 2010 and is based in Greenwood Village, Colorado. As of May 31, 2019, Silvergate Pharmaceuticals, Inc. operates as a subsidiary of CutisPharma Inc.